Safety and Immunogenicity of mRNA Vaccines Against Severe Acute Respiratory Syndrome Coronavirus 2 in Patients With Lung Cancer Receiving Immune Checkpoint Inhibitors: A Multicenter Observational Study in Japan

Longitudinal COVID-19-vaccination-induced antibody responses and Omicron neutralization in patients with lung cancer

(2022) Philip C. Mack et al.   CANCER CELL

Short-term safety of the BNT162b2 mRNA COVID-19 vaccine in patients with cancer treated with immune checkpoint inhibitors

(2021) Barliz Waissengrin et al.   LANCET ONCOLOGY

Antibody responses to the BNT162b2 mRNA vaccine in individuals previously infected with SARS-CoV-2

(2021) Joseph E. Ebinger et al.   NATURE MEDICINE

Association of clinical factors and recent anticancer therapy with COVID-19 severity among patients with cancer: a report from the COVID-19 and Cancer Consortium

(2021) P. Grivas et al.   ANNALS OF ONCOLOGY

COVID-19 mRNA vaccines and immune-related adverse events in cancer patients treated with immune checkpoint inhibitors

(2021) Yu-Wei Chen et al.   EUROPEAN JOURNAL OF CANCER

Low titers of SARS-CoV-2 neutralizing antibodies after first vaccination dose in cancer patients receiving checkpoint inhibitors

(2021) Evangelos Terpos et al.   Journal of Hematology & Oncology

mRNA-1273 COVID-19 vaccination in patients receiving chemotherapy, immunotherapy, or chemoimmunotherapy for solid tumours: a prospective, multicentre, non-inferiority trial

(2021) Sjoukje F Oosting et al.   LANCET ONCOLOGY

Immunogenicity and safety of influenza vaccination in cancer patients receiving checkpoint inhibitors targeting PD-1 or PD-L1

(2020) A. Bayle et al.   ANNALS OF ONCOLOGY

Updated Analysis From KEYNOTE-189: Pembrolizumab or Placebo Plus Pemetrexed and Platinum for Previously Untreated Metastatic Nonsquamous Non–Small-Cell Lung Cancer

(2020) Shirish Gadgeel et al.   JOURNAL OF CLINICAL ONCOLOGY

Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study

(2020) Nicole M Kuderer et al.   LANCET

Economic Consequences of the COVID-19 Outbreak: the Need for Epidemic Preparedness

(2020) Anton Pak et al.   Frontiers in Public Health

A Randomized, Placebo-Controlled Trial of Pembrolizumab Plus Chemotherapy in Patients With Metastatic Squamous Non–Small-Cell Lung Cancer: Protocol-Specified Final Analysis of KEYNOTE-407

(2020) Luis Paz-Ares et al.   Journal of Thoracic Oncology

COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines

(2020) Mohd. Iqbal Yatoo et al.   Human Vaccines & Immunotherapeutics

Efficacy and Toxicity of Immune -Checkpoint Inhibitors in Patients With Preexisting Autoimmune Disorders

(2020) Michelle Coureau et al.   Frontiers in Medicine

COVID-19 and Cancer: Current Challenges and Perspectives

(2020) Ziad Bakouny et al.   CANCER CELL

Vaccination and Immune Checkpoint Inhibitors

(2020) Anne-Laure Desage et al.   AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS

Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

(2020) Lindsey R. Baden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

(2020) Fernando P. Polack et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors (ICI)

(2019) Curtis R Chong et al.   CLINICAL INFECTIOUS DISEASES

Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial

(2019) Tony S K Mok et al.   LANCET

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

(2019) Luis Paz-Ares et al.   LANCET

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non–Small-Cell Lung Cancer

(2018) Koji Haratani et al.   JAMA Oncology

Influenza vaccination in patients with lung cancer receiving anti–programmed death receptor 1 immunotherapy does not induce immune-related adverse events

(2018) Dirk H. Wijn et al.   EUROPEAN JOURNAL OF CANCER

Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

(2017) Scott J. Antonia et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer

(2016) Martin Reck et al.   NEW ENGLAND JOURNAL OF MEDICINE